Joglekar lab receives an Innovative Immunotherapies Award

Joglekar lab receives a new grant titled "Reprogramming Treg Cell Specificity to Suppress Autoreactivity in T1D" from the Juvenile Diabetes Research Foundation. This project will test the ability of novel immune receptors to reprogram T cells and suppress diabetogenic T cells in vitro.